Neumedicines Inc.’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation
1/8/2014 9:06:43 AM
PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT) for use in cancer patients, today announced results from a blinded, randomized, placebo-controlled study that demonstrate a significant increase in survival in non-human primates treated with a single, low-dose, subcutaneous injection of HemaMax™ (recombinant human interleukin-12) versus control (56% versus 36%; p<0.05) 60 days after exposure to lethal radiation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by